Haemonetics Corporation (HAE) reported a 5% revenue increase in its Hospital business during the fiscal second quarter, supported by a 12% growth in Blood Management Technologies. The company has a market capitalization of $4.08 billion and has surpassed earnings expectations in three of the last four quarters, achieving an average surprise of 6%. However, HAE faces concerns with foreign exchange impacts on international sales, which accounted for 26.6% of its fiscal second-quarter revenue, and a debt-to-capital ratio of 52% due to $920 million in long-term debt.
HAE’s NexSys PCS system continues to thrive with over 40 million collections, reducing donor door-to-door time by an average of 16 minutes. Despite a positive outlook on hospital growth and product adoption, the company is cautious about weak macroeconomic conditions and foreign exchange fluctuations, which could affect operations moving forward. The consensus estimate for fiscal 2026 earnings stands at $4.93 per share, with revenues projected at $1.32 billion, indicating a 3.2% increase from the previous year.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
